OBJECTIVE: There has been an increased focus on the region adjacent to the lateral ventricles (LV) as a potential source of malignant tumors and/or more aggressive disease. We set out to determine if glioblastoma multiforme (GBM) bordering the LV was associated with decreased survival as compared to non-LV GBM. METHODS: We reviewed the clinical records of 69 consecutive patients undergoing craniotomy for GBM at a single academic institution. Twenty-six patients were identified with contrast-enhancing lesions (CEL) bordering the LV (LV CEL). These 26 patients were matched with 26 patients with CEL not bordering the LV (non-LV CEL). These cohorts were matched for factors consistently shown to be associated with survival, which were age, tumor size, Karnofsky performance score, extent of resection, Gliadel implantation, and Temodar chemotherapy. Overall survival was compared between the cohorts via Log-rank analysis. RESULTS: Despite similarities in pre-operative clinical status, tumor size, peri-operative outcome, and treatment regimens, the median survival for patients with LV CEL was significantly decreased as compared to patients with non-LV CEL (8 months vs. 11 months), P = 0.02. Additionally, survival analysis in patients stratified by primary and secondary resection also demonstrated a strong trend towards decreased survival after resection of LV CEL. After primary and secondary resection, patients with LV CEL versus non-LV CEL had a median survival of 11 months vs. 14 months (P = 0.10) and 7 months vs. 10 months (P = 0.11), respectively. CONCLUSION: While the causal factors underlying this observation are not provided with this observational study, GBM bordering the LV may carry a prognostic significance.
OBJECTIVE: There has been an increased focus on the region adjacent to the lateral ventricles (LV) as a potential source of malignant tumors and/or more aggressive disease. We set out to determine if glioblastoma multiforme (GBM) bordering the LV was associated with decreased survival as compared to non-LV GBM. METHODS: We reviewed the clinical records of 69 consecutive patients undergoing craniotomy for GBM at a single academic institution. Twenty-six patients were identified with contrast-enhancing lesions (CEL) bordering the LV (LV CEL). These 26 patients were matched with 26 patients with CEL not bordering the LV (non-LV CEL). These cohorts were matched for factors consistently shown to be associated with survival, which were age, tumor size, Karnofsky performance score, extent of resection, Gliadel implantation, and Temodar chemotherapy. Overall survival was compared between the cohorts via Log-rank analysis. RESULTS: Despite similarities in pre-operative clinical status, tumor size, peri-operative outcome, and treatment regimens, the median survival for patients with LV CEL was significantly decreased as compared to patients with non-LV CEL (8 months vs. 11 months), P = 0.02. Additionally, survival analysis in patients stratified by primary and secondary resection also demonstrated a strong trend towards decreased survival after resection of LV CEL. After primary and secondary resection, patients with LV CEL versus non-LV CEL had a median survival of 11 months vs. 14 months (P = 0.10) and 7 months vs. 10 months (P = 0.11), respectively. CONCLUSION: While the causal factors underlying this observation are not provided with this observational study, GBM bordering the LV may carry a prognostic significance.
Authors: Christopher Calabrese; Helen Poppleton; Mehmet Kocak; Twala L Hogg; Christine Fuller; Blair Hamner; Eun Young Oh; M Waleed Gaber; David Finklestein; Meredith Allen; Adrian Frank; Ildar T Bayazitov; Stanislav S Zakharenko; Amar Gajjar; Andrew Davidoff; Richard J Gilbertson Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: Todd M Savarese; Taichang Jang; Hoi Pang Low; Rebecca Salmonsen; N Scott Litofsky; Zdenka Matuasevic; Alonzo H Ross; Lawrence D Recht Journal: J Neurosurg Date: 2005-01 Impact factor: 5.115
Authors: Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada Journal: Cancer Cell Date: 2005-08 Impact factor: 31.743
Authors: Daniel A Lim; Soonmee Cha; Mary C Mayo; Mei-Hsiu Chen; Evren Keles; Scott VandenBerg; Mitchel S Berger Journal: Neuro Oncol Date: 2007-07-10 Impact factor: 12.300
Authors: Tyler C Steed; Jeffrey M Treiber; Birra Taha; H Billur Engin; Hannah Carter; Kunal S Patel; Anders M Dale; Bob S Carter; Clark C Chen Journal: J Neurooncol Date: 2020-06-15 Impact factor: 4.130
Authors: Kaisorn L Chaichana; Ignacio Jusue-Torres; Rodrigo Navarro-Ramirez; Shaan M Raza; Maria Pascual-Gallego; Aly Ibrahim; Marta Hernandez-Hermann; Luis Gomez; Xiaobu Ye; Jon D Weingart; Alessandro Olivi; Jaishri Blakeley; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quinones-Hinojosa Journal: Neuro Oncol Date: 2013-11-26 Impact factor: 12.300
Authors: Brittanie Partridge; John H Rossmeisl; Alexandra M Kaloss; Erwin Kristobal Gudenschwager Basso; Michelle H Theus Journal: J Neurosci Methods Date: 2020-02-14 Impact factor: 2.390
Authors: Melanie Kappadakunnel; Ascia Eskin; Jun Dong; Stanley F Nelson; Paul S Mischel; Linda M Liau; Phioanh Ngheimphu; Albert Lai; Timothy F Cloughesy; Jonathan Goldin; Whitney B Pope Journal: J Neurooncol Date: 2009-08-05 Impact factor: 4.130